CN109641843B - 作为apj激动剂的4-羟基-3-磺酰基吡啶-2(1h)-酮 - Google Patents
作为apj激动剂的4-羟基-3-磺酰基吡啶-2(1h)-酮 Download PDFInfo
- Publication number
- CN109641843B CN109641843B CN201780049629.7A CN201780049629A CN109641843B CN 109641843 B CN109641843 B CN 109641843B CN 201780049629 A CN201780049629 A CN 201780049629A CN 109641843 B CN109641843 B CN 109641843B
- Authority
- CN
- China
- Prior art keywords
- dimethoxyphenyl
- sulfonyl
- butyl
- substituted
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349719P | 2016-06-14 | 2016-06-14 | |
| US62/349,719 | 2016-06-14 | ||
| PCT/US2017/037370 WO2017218617A1 (en) | 2016-06-14 | 2017-06-14 | 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109641843A CN109641843A (zh) | 2019-04-16 |
| CN109641843B true CN109641843B (zh) | 2022-07-19 |
Family
ID=59091682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780049629.7A Active CN109641843B (zh) | 2016-06-14 | 2017-06-14 | 作为apj激动剂的4-羟基-3-磺酰基吡啶-2(1h)-酮 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10889565B2 (https=) |
| EP (1) | EP3468952B1 (https=) |
| JP (1) | JP6962941B2 (https=) |
| KR (1) | KR102521955B1 (https=) |
| CN (1) | CN109641843B (https=) |
| ES (1) | ES2844184T3 (https=) |
| WO (1) | WO2017218617A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016196771A1 (en) | 2015-06-03 | 2016-12-08 | Bristol-Myers Squibb Company | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
| KR102707502B1 (ko) | 2015-10-14 | 2024-09-13 | 브리스톨-마이어스 스큅 컴퍼니 | Apj 효능제로서의 2,4-디히드록시-니코틴아미드 |
| UY37005A (es) | 2015-12-04 | 2017-06-30 | Bristol-Myers Squibb Company Una Corporacion Del Estado De Delaware | Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos |
| BR112018012112A2 (pt) | 2015-12-16 | 2018-12-04 | Bristol-Myers Squibb Company | heteroaril-hidroxipirimidinonas como agonistas do receptor apj |
| TWI744301B (zh) | 2016-03-24 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺 |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| KR102384668B1 (ko) | 2016-06-14 | 2022-04-07 | 브리스톨-마이어스 스큅 컴퍼니 | Apj 효능제로서의 6-히드록시-5-(페닐/헤테로아릴술포닐)피리미딘-4(1h)-온 |
| JP7037558B2 (ja) * | 2016-10-14 | 2022-03-16 | ブリストル－マイヤーズ スクイブ カンパニー | ３－スルホニル－５－アミノピリジン－２，４－ジオール ａｐｊアゴニスト |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| WO2018093576A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| US11020395B2 (en) | 2016-11-16 | 2021-06-01 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor |
| US11149040B2 (en) | 2017-11-03 | 2021-10-19 | Amgen Inc. | Fused triazole agonists of the APJ receptor |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| US12134611B2 (en) | 2018-11-13 | 2024-11-05 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| EP3880673B1 (en) * | 2018-11-13 | 2024-01-03 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0931061A (ja) * | 1995-07-24 | 1997-02-04 | Suntory Ltd | ヒダントイン誘導体およびその用途 |
| JPH09505292A (ja) * | 1993-11-19 | 1997-05-27 | パーク・デイビス・アンド・カンパニー | プロテアーゼ阻害剤および抗ウイルス剤としての５，６−ジヒドロピロン誘導体 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3847927A (en) * | 1972-12-20 | 1974-11-12 | Dow Chemical Co | Sulfur-containing hydroxypyridones |
| FI962019A7 (fi) * | 1993-11-19 | 1996-05-20 | Parke Davis & Co | Pyronijohdannaiset proteaasi-inhibiittoreina ja antiviraalisina ainein a |
| EP0721944B1 (en) * | 1994-07-29 | 2001-01-17 | Suntory Limited | Imidazolidine derivative and use thereof |
| US10570128B2 (en) | 2014-05-28 | 2020-02-25 | Sanford Burnham Prebys Medical Discovery Institute | Agonists of the apelin receptor and methods of use thereof |
| WO2016196771A1 (en) * | 2015-06-03 | 2016-12-08 | Bristol-Myers Squibb Company | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
| KR102707502B1 (ko) * | 2015-10-14 | 2024-09-13 | 브리스톨-마이어스 스큅 컴퍼니 | Apj 효능제로서의 2,4-디히드록시-니코틴아미드 |
| UY37005A (es) | 2015-12-04 | 2017-06-30 | Bristol-Myers Squibb Company Una Corporacion Del Estado De Delaware | Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos |
| BR112018012112A2 (pt) | 2015-12-16 | 2018-12-04 | Bristol-Myers Squibb Company | heteroaril-hidroxipirimidinonas como agonistas do receptor apj |
| TWI744301B (zh) | 2016-03-24 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺 |
| KR102384668B1 (ko) | 2016-06-14 | 2022-04-07 | 브리스톨-마이어스 스큅 컴퍼니 | Apj 효능제로서의 6-히드록시-5-(페닐/헤테로아릴술포닐)피리미딘-4(1h)-온 |
| JP7037558B2 (ja) * | 2016-10-14 | 2022-03-16 | ブリストル－マイヤーズ スクイブ カンパニー | ３－スルホニル－５－アミノピリジン－２，４－ジオール ａｐｊアゴニスト |
-
2017
- 2017-06-14 JP JP2018565337A patent/JP6962941B2/ja active Active
- 2017-06-14 CN CN201780049629.7A patent/CN109641843B/zh active Active
- 2017-06-14 KR KR1020197000801A patent/KR102521955B1/ko active Active
- 2017-06-14 WO PCT/US2017/037370 patent/WO2017218617A1/en not_active Ceased
- 2017-06-14 US US16/309,168 patent/US10889565B2/en active Active
- 2017-06-14 EP EP17731794.8A patent/EP3468952B1/en active Active
- 2017-06-14 ES ES17731794T patent/ES2844184T3/es active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09505292A (ja) * | 1993-11-19 | 1997-05-27 | パーク・デイビス・アンド・カンパニー | プロテアーゼ阻害剤および抗ウイルス剤としての５，６−ジヒドロピロン誘導体 |
| US5936128A (en) * | 1993-11-19 | 1999-08-10 | Warner-Lambert Company | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents |
| JPH0931061A (ja) * | 1995-07-24 | 1997-02-04 | Suntory Ltd | ヒダントイン誘導体およびその用途 |
Non-Patent Citations (1)
| Title |
|---|
| Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases;Jiangang Cao et al;《Current Drug Targets》;20151231;第16卷(第2期);1-15 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102521955B1 (ko) | 2023-04-13 |
| US10889565B2 (en) | 2021-01-12 |
| US20190330186A1 (en) | 2019-10-31 |
| WO2017218617A1 (en) | 2017-12-21 |
| JP2019518041A (ja) | 2019-06-27 |
| KR20190017931A (ko) | 2019-02-20 |
| ES2844184T3 (es) | 2021-07-21 |
| CN109641843A (zh) | 2019-04-16 |
| JP6962941B2 (ja) | 2021-11-05 |
| EP3468952A1 (en) | 2019-04-17 |
| EP3468952B1 (en) | 2020-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109641843B (zh) | 作为apj激动剂的4-羟基-3-磺酰基吡啶-2(1h)-酮 | |
| CN109311821B (zh) | 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮 | |
| JP7037558B2 (ja) | ３－スルホニル－５－アミノピリジン－２，４－ジオール ａｐｊアゴニスト | |
| CN108368087B (zh) | 作为apj激动剂的2，4-二羟基-烟酰胺 | |
| JP7155102B2 (ja) | Ｒｏｃｋ阻害剤としてのスピロ縮合環尿素 | |
| CN107922401B (zh) | 用于治疗心血管病症的4-羟基-3-(杂芳基)吡啶-2-酮apj激动剂 | |
| KR102678264B1 (ko) | 아펠린 수용체 효능제 및 사용 방법 | |
| CN109195963B (zh) | 作为apj激动剂的6-羟基-4-氧代-1，4-二氢嘧啶-5-甲酰胺 | |
| JP6948322B2 (ja) | Ａｐｊ受容体のａｐｊアゴニストとしてのヘテロアリールヒドロキシピリミジノン | |
| KR102291444B1 (ko) | 디히드로피리디논 mgat2 억제제 | |
| WO2015191681A2 (en) | Substituted pyridinones as mgat2 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |